156 related articles for article (PubMed ID: 30191677)
1. High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate.
Zhao S; Molina A; Yu A; Hanson J; Cheung H; Li X; Natkunam Y
J Pathol Clin Res; 2019 Jan; 5(1):12-24. PubMed ID: 30191677
[TBL] [Abstract][Full Text] [Related]
2. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.
Li X; Abrahams C; Yu A; Embry M; Henningsen R; DeAlmeida V; Matheny S; Kline T; Yam A; Stafford R; Hallam T; Lupher M; Molina A
Oncotarget; 2023 Jan; 14():1-13. PubMed ID: 36634212
[TBL] [Abstract][Full Text] [Related]
4. CD137 ligand is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications.
Zhao S; Zhang H; Xing Y; Natkunam Y
Am J Surg Pathol; 2013 Feb; 37(2):250-8. PubMed ID: 23095505
[TBL] [Abstract][Full Text] [Related]
5. CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.
Zeiner PS; Zinke J; Kowalewski DJ; Bernatz S; Tichy J; Ronellenfitsch MW; Thorsen F; Berger A; Forster MT; Muller A; Steinbach JP; Beschorner R; Wischhusen J; Kvasnicka HM; Plate KH; Stefanović S; Weide B; Mittelbronn M; Harter PN
Acta Neuropathol Commun; 2018 Mar; 6(1):18. PubMed ID: 29490700
[TBL] [Abstract][Full Text] [Related]
6. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.
Datta MW; Shahsafaei A; Nadler LM; Freeman GJ; Dorfman DM
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):210-5. PubMed ID: 10981873
[TBL] [Abstract][Full Text] [Related]
7. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
8. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
9. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.
Anderson MW; Zhao S; Freud AG; Czerwinski DK; Kohrt H; Alizadeh AA; Houot R; Azambuja D; Biasoli I; Morais JC; Spector N; Molina-Kirsch HF; Warnke RA; Levy R; Natkunam Y
Am J Pathol; 2012 Sep; 181(3):795-803. PubMed ID: 22901750
[TBL] [Abstract][Full Text] [Related]
10. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders.
Yoon SO; Kim WY; Go H; Paik JH; Kim JE; Kim YA; Huh JR; Jeon YK; Kim CW
Am J Surg Pathol; 2010 May; 34(5):645-55. PubMed ID: 20220512
[TBL] [Abstract][Full Text] [Related]
11. Differentiating germinal center-derived lymphomas through their cellular microenvironment.
Carbone A; Gloghini A; Cabras A; Elia G
Am J Hematol; 2009 Jul; 84(7):435-8. PubMed ID: 19484731
[TBL] [Abstract][Full Text] [Related]
12. EBV associated lymphomas in 2008 WHO classification.
Zhang T; Fu Q; Gao D; Ge L; Sun L; Zhai Q
Pathol Res Pract; 2014 Feb; 210(2):69-73. PubMed ID: 24355441
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclin D2 and D3 in lymphoid lesions.
Teramoto N; Pokrovskaja K; Szekely L; Polack A; Yoshino T; Akagi T; Klein G
Int J Cancer; 1999 May; 81(4):543-50. PubMed ID: 10225442
[TBL] [Abstract][Full Text] [Related]
14. [Nasal and pharyngeal non-Hodgkin lymphomas and their relationship with Epstein-Barr virus: a report of 158 cases].
He YJ; Jia XS; Hasui K; Wang EH; He AG
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):94-7. PubMed ID: 17493382
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
16. The leukocyte semaphorin CD100 is expressed in most T-cell, but few B-cell, non-Hodgkin's lymphomas.
Dorfman DM; Shahsafaei A; Nadler LM; Freeman GJ
Am J Pathol; 1998 Jul; 153(1):255-62. PubMed ID: 9665486
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
18. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas.
Copie-Bergman C; Plonquet A; Alonso MA; Boulland ML; Marquet J; Divine M; Möller P; Leroy K; Gaulard P
Mod Pathol; 2002 Nov; 15(11):1172-80. PubMed ID: 12429796
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
20. Microvillous lymphomas are B-cell neoplasms that frequently express CD56.
Hammer RD; Vnencak-Jones CL; Manning SS; Glick AD; Kinney MC
Mod Pathol; 1998 Mar; 11(3):239-46. PubMed ID: 9521469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
